Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer

Selpercatinib, a RET kinase inhibitor, is an effective treatment for patients with medullary thyroid cancer with RET mutations. In this paper, we present the case of a 62-year-old man with ectopic Cushing’s syndrome due to medullary thyroid cancer who received treatment with selpercatinib. Six month...

Descripción completa

Detalles Bibliográficos
Autores principales: Ragnarsson, Oskar, Piasecka, Marta, Hallqvist, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139362/
https://www.ncbi.nlm.nih.gov/pubmed/35621672
http://dx.doi.org/10.3390/curroncol29050282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139362/
https://www.ncbi.nlm.nih.gov/pubmed/35621672
http://dx.doi.org/10.3390/curroncol29050282

Ejemplares similares